SAGE Therapeutics (NASDAQ: SAGE) reported Q4 EPS of ($1.56), $0.06 worse than the analyst estimate of ($1.50). Revenue for the quarter came in at $12.81 million versus the consensus estimate of $14.08 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.